Secukinumab B
Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
Product Specifications
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
IL Receptor
CAS Number
1229022-83-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
M32625-01 100 mg
2-Methoxyphenyl-4-propylene-1-O-beta-apiofuranosyl- (1-6) -beta-glucopyranoside
Ask
View Details 
M32625-02 50 mg
2-Methoxyphenyl-4-propylene-1-O-beta-apiofuranosyl- (1-6) -beta-glucopyranoside
Ask
View Details 
M32625-03 5 mg
2-Methoxyphenyl-4-propylene-1-O-beta-apiofuranosyl- (1-6) -beta-glucopyranoside
Ask
View Details 